GlassScriptPhysician profile
Anand Thakur
NPI 1467459412
$101,744.79
in general payments reported to CMS, 2019-2025
36 companies · $368 in 2025
The $368 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75K · 2020: $20K · 2021: $2,155 · 2022: $3,193 · 2023: $357 · 2024: $338 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040 · Education: $23.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.58 |
| Education | $23.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $79,516.34 | 2019-2021 | |
| Nevro Corp. | $5,674.61 | 2019-2024 | Senza |
| Kaleo, INC. | $4,632.62 | 2019 | |
| Daiichi Sankyo INC. | $3,458.45 | 2019 | |
| Mml US, INC. | $1,405.36 | 2022 | |
| Vertiflex, INC. | $1,364.38 | 2019 | |
| Medtronic, INC. | $1,180.45 | 2021-2024 | Intellis Adaptivestim |
| Painteq LLC | $1,061.61 | 2022-2024 | Painteq |
| Boston Scientific Corporation | $656.29 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Intracept |
| Abbott Laboratories | $467.01 | 2019-2025 | Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $395.72 | 2019-2021 | |
| Medtronic USA, INC. | $257.68 | 2019 | |
| Curonix LLC | $257.42 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Vertos Medical, INC. | $208.14 | 2022-2024 | Mild Device Kit |
| Collegium Pharmaceutical, INC. | $196.07 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $149.92 | 2019 | |
| Mdd US Operations, LLC | $127.87 | 2019-2020 | |
| Sentynl Therapeutics, INC. | $94.85 | 2019-2020 | |
| Saluda Medical Americas, INC. | $86.06 | 2025 | Evoke |
| Uswm, LLC | $61.23 | 2021 | |
| Pfizer INC. | $53.59 | 2019-2021 | |
| Foundation Fusion Solutions, LLC | $49.02 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $44.83 | 2024-2025 | |
| Bausch Health US, LLC | $42.05 | 2019 | |
| Tersera Therapeutics LLC | $39.36 | 2019 | |
| Stimwave Technologies Incorporated | $38.90 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.74 | 2019-2021 | |
| Amgen INC. | $29.14 | 2019-2022 | |
| Grt US Holding, INC. | $27.36 | 2020-2021 | |
| Stryker Corporation | $24.71 | 2021 | |
| Nalu Medical, INC. | $22.86 | 2024 | Nalu Neurostimulation System |
| Zyla Life Sciences, INC. | $21.99 | 2019 | |
| Pinnacle, INC | $20.72 | 2020 | |
| Alkermes, INC. | $18.64 | 2021 | |
| Spinal Simplicity, LLC | $16.82 | 2021 | |
| Assertio Therapeutics, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anand Thakur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.